PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes

Amgen's report of higher sales and news of priority review for an outcomes benefit claim for Repatha bode well, but a negative JAMA editorial is another knock on the PCSK9 inhibitor class.